Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
|Articles|July 1, 2007
Countering vitiligo
Vitiligo patients can benefit from any number of therapies offered by dermatologists. One expert discusses the etiologies of this hypopigmentary disorder, its various treatments and its therapeutic challenges.
Advertisement
Advertisement
Related to this article
Phase 2 data presented at EADV 2026 showed daxdilimab significantly reduced disease activity and improved response rates in treatment-refractory DLE.
Presented as a late breaker at EADV 2026, mid-dose zumilokibart achieved EASI-75 in 65.9% of adults with atopic dermatitis vs 23.4% with placebo at week 16.
This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.
EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Dermatology Times is looking back on the top stories in dermatology from the month of September.
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Data at EADV 2026 Highlight Outcomes Across AD, CSU, and Prurigo Nodularis
2
Late Breaking: Zumilokibart Meets Primary End Point in Phase 2 Atopic Dermatitis Trial
3
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
4
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
5